How viral infections associated with cancer become persistent?

August 17, 2020

Kaposi's sarcoma-associated herpesvirus (KSHV) is one of the seven known viruses that causes cancer in humans and is responsible for Kaposi's sarcoma, a disease linked to immunosuppression mainly associated with AIDS. There are no specific therapies for these tumors, and prognosis can be very poor. Now, a new study led by Pedro Simas, group leader at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) and Professor at Faculdade de Medicina da Universidade de Lisboa (FMUL) and Universidade Católica Portuguesa (UCP) and Kenneth M. Kaye, Professor at Harvard Medical School (HMS; USA), discovered a region of viral protein LANA that is key for viral latency and persistent infection inside human cells. These findings published today in the prestigious journal Proceedings of the National Academy of Sciences of the United States of America (PNAS)*, can potentially be used to develop therapy for KSHV tumors since blocking the function of this LANA region is expected to abolish virus persistence, which would eliminate the cancer cells.

KSHV infects human cells, primarily lymphocytes (a type of white blood cells), and through this infection expresses its own genes in the cell, taking over its growth mechanisms causing it to grow out of control, eventually causing cancer, such as Kaposi's Sarcoma (KS) or a type of lymphoma termed primary effusion lymphoma. Therefore, understanding how viruses modulate host cell function is central to prospects for potential therapies. Critical to this are the viral proteins expressed during the latent phase of infection, which make the virus persist inside these cells and among them, the latency-associated nuclear antigen - LANA - is a central coordinator of the replication and persistence of viral genomes inside host cells.

"Our research group studies the functions of this viral protein LANA for many years. Now, we have discovered a region of LANA that is key for virus to persist. Of particular interest, this LANA region preferentially interacts with a form of a well-known tumor suppressor protein called p53. The interesting aspect of this discovery is that this region, an acidic domain reader, discerns the presence of a specific post-translation modification, acetylation, an add-on attribute that proteins might acquire while they are being produced by the cell", explains Pedro Simas, senior author of this study. These modifications determine the structure of a protein therefore its function. Through a series of genetic and biochemical experiments using models of infection, researchers now show that the interaction of this specific "reader" region of LANA with unacetylated p53, or possibly other unacetylated proteins may allow the virus to persist in tumor cells.

The finding that KSHV has evolved a mechanism for this type of protein interaction underscores the physiological importance of post-translational modifications in the regulation of persistence infections", explains Pedro Simas. "These findings could potentially be used to develop therapy of KSHV tumors since blocking the function of this LANA region is expected to abolish virus persistence, which would kill the cancer cells", adds senior author Kenneth M. Kaye.
This study was performed at iMM and Brigham and Women's Hospital and Harvard Medical School and funded by the National Institutes of Health (NIH; USA), Fondation ARC pour la recherche sur le cancer (Fondation ARC) and Fundação para a Ciência e a Tecnologia (FCT; Portugal).

*Franceline Juillard#, Marta Pires de Miranda#, Shijun Li, Aura Franco, Andre? F. Seixas, Bing Liua, A?ngel L. A?lvarez, Min Tan, Agnieszka Szymula, Kenneth M. Kaye* and J. Pedro Simas*(2020) KSHV LANA acetylation-selective acidic domain reader sequence mediates virus persistence. Proc. Natl. Acad. Sci. U.S.A. DOI: 10.1073/pnas.2004809117

Instituto de Medicina Molecular

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to